Pharmacological inhibitors of glycogen synthase kinase 3.

By L. Meijer, M. Flajolet, Paul Greengard. TIPS - Trends in Pharmacological Sciences, 2004

608 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

SCF/β-TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner (2011, background): “Now we report that a potent and selective inhibitor of GSK-3, SB216367 (arylindolemaleimide, IC50 34 nM) (and data not shown with CT99021, aminopyrimidine IC50 10 nM (31)) as well as siRNAs against GSK-3 isoforms produce an increase in the level of Nrf2 protein.”
Functional redundancy of GSK-3α and GSK-3β in wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines (2007, background): “Most inhibitors of GSK-3 cannot discriminate between GSK-3α or β based on their ATPcompetitive mode of action (Meijer et al., 2004).”
Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1 (2010, methodology): “To determine whether Eomes expression is responsive to activation of Wnt signaling, we used 6-bromo-substituted indirubin-acetoxime (BIO-acetoxime), a specific inhibitor of GSK-3b, to block b-catenin phosphorylation and degradation (Meijer et al., 2004).”